Amgen (AMGN) Stock Forecast & Price Target

Compare

6,816 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

14 Buy

10 Hold

1 Sell

Based on 25 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$360.14

▼(-4.09% Downside)

Based on 25 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $360.14 with a high forecast of $432.00 and a low forecast of $185.00. The average price target represents a -4.09% change from the last price of $375.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"184":"$184","433":"$433","246.25":"$246.3","308.5":"$308.5","370.75":"$370.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$432.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":360.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$360.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$185.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[184,246.25,308.5,370.75,433],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,342.308,349.2073846153846,356.1067692307692,363.00615384615384,369.90553846153847,376.80492307692305,383.7043076923077,390.6036923076923,397.50307692307695,404.4024615384615,411.30184615384616,418.20123076923073,425.10061538461537,{"y":432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,342.308,343.6796923076923,345.0513846153846,346.4230769230769,347.79476923076925,349.16646153846153,350.5381538461538,351.90984615384616,353.28153846153845,354.65323076923073,356.0249230769231,357.39661538461536,358.7683076923077,{"y":360.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,342.308,330.2073846153846,318.1067692307692,306.00615384615384,293.90553846153847,281.80492307692305,269.7043076923077,257.6036923076923,245.50307692307692,233.40246153846152,221.30184615384616,209.20123076923076,197.10061538461537,{"y":185,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":274.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.689,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.584,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.147,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":282.167,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.393,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":283.706,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.346,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.277,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.167,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.057,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":342.308,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$432.00

Average Price Target$360.14

Lowest Price Target$185.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mohit Bansal

Wells Fargo

$325→$375

Hold

-0.13%

Downside

Reiterated

02/19/26

Amgen price target raised to $375 from $325 at Wells FargoAmgen price target raised to $375 from $325 at Wells Fargo

Emily Field

Barclays

$185

Hold

-50.73%

Downside

Initiated

02/19/26

Amgen initiated with an Equal Weight at BarclaysAmgen initiated with an Equal Weight at Barclays

David Amsellem

Piper Sandler

$381→$432

Buy

15.05%

Upside

Reiterated

02/18/26

Amgen price target raised to $432 from $381 at Piper SandlerAmgen price target raised to $432 from $381 at Piper Sandler

Salim Syed

Mizuho Securities

$280→$295

Hold

-21.44%

Downside

Reiterated

02/11/26

Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho

Unknown Analyst

Argus Research

Not Ranked

Argus Research

$400

Buy

6.52%

Upside

Reiterated

02/06/26

Amgen (AMGN) Receives a Buy from Argus Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$305→$347

Hold

-7.59%

Downside

Reiterated

02/05/26

Guggenheim Remains a Hold on Amgen (AMGN)

Gregory Renza

Truist Financial

$319

Hold

-15.05%

Downside

Reiterated

02/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Sarepta Therapeutics (NASDAQ: SRPT) and Protagonist Therapeutics (NASDAQ: PTGX)

Terence Flynn

Morgan Stanley

$304→$309

Hold

-17.71%

Downside

Reiterated

02/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Caribou Biosciences (NASDAQ: CRBU) and Boston Scientific (NYSE: BSX)

Evan Seigerman

BMO Capital

$372

Buy

-0.93%

Downside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Geoff Meacham

Citi

$315→$345

Hold

-8.12%

Downside

Reiterated

02/04/26

Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating

Salveen Richter

Goldman Sachs

$415

Buy

10.52%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ)

Matt Phipps

William Blair

Buy

―

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)

Carter Gould

Cantor Fitzgerald

$315→$350

Hold

-6.79%

Downside

Reiterated

02/04/26

Cantor Fitzgerald Sticks to Its Hold Rating for Amgen (AMGN)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

02/04/26

Evercore ISI Remains a Buy on Amgen (AMGN)

Louise Chen

Scotiabank

$385

Buy

2.53%

Upside

Reiterated

02/04/26

Scotiabank Keeps Their Buy Rating on Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mohit Bansal

Wells Fargo

$325→$375

Hold

-0.13%

Downside

Reiterated

02/19/26

Amgen price target raised to $375 from $325 at Wells FargoAmgen price target raised to $375 from $325 at Wells Fargo

Emily Field

Barclays

$185

Hold

-50.73%

Downside

Initiated

02/19/26

Amgen initiated with an Equal Weight at BarclaysAmgen initiated with an Equal Weight at Barclays

David Amsellem

Piper Sandler

$381→$432

Buy

15.05%

Upside

Reiterated

02/18/26

Amgen price target raised to $432 from $381 at Piper SandlerAmgen price target raised to $432 from $381 at Piper Sandler

Salim Syed

Mizuho Securities

$280→$295

Hold

-21.44%

Downside

Reiterated

02/11/26

Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho

Unknown Analyst

Argus Research

Not Ranked

Argus Research

$400

Buy

6.52%

Upside

Reiterated

02/06/26

Amgen (AMGN) Receives a Buy from Argus Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$305→$347

Hold

-7.59%

Downside

Reiterated

02/05/26

Guggenheim Remains a Hold on Amgen (AMGN)

Gregory Renza

Truist Financial

$319

Hold

-15.05%

Downside

Reiterated

02/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Sarepta Therapeutics (NASDAQ: SRPT) and Protagonist Therapeutics (NASDAQ: PTGX)

Terence Flynn

Morgan Stanley

$304→$309

Hold

-17.71%

Downside

Reiterated

02/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Caribou Biosciences (NASDAQ: CRBU) and Boston Scientific (NYSE: BSX)

Evan Seigerman

BMO Capital

$372

Buy

-0.93%

Downside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Geoff Meacham

Citi

$315→$345

Hold

-8.12%

Downside

Reiterated

02/04/26

Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating

Salveen Richter

Goldman Sachs

$415

Buy

10.52%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ)

Matt Phipps

William Blair

Buy

―

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)

Carter Gould

Cantor Fitzgerald

$315→$350

Hold

-6.79%

Downside

Reiterated

02/04/26

Cantor Fitzgerald Sticks to Its Hold Rating for Amgen (AMGN)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

02/04/26

Evercore ISI Remains a Buy on Amgen (AMGN)

Louise Chen

Scotiabank

$385

Buy

2.53%

Upside

Reiterated

02/04/26

Scotiabank Keeps Their Buy Rating on Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

xxx

Success Rate

11/14 ratings generated profit

Average Return

+7.94%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +7.94% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

14/14 ratings generated profit

Average Return

+25.41%

a rating ―

Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.41% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+29.49%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 32 Buy Ratings, 18 Hold Ratings, and 2 Sell Ratings. AMGN average Analyst price target in the past 3 months is 360.14.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $4.81 with a range of $4.17 to $6.15. The previous quarter’s EPS was $5.29. AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $8.62B with a range of $8.32B to $9.26B. The previous quarter’s sales results were $9.90B. AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 360.14.

What is AMGN’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for AMGN, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy which is based on 14 buy ratings, 10 hold ratings and 1 sell ratings.

What is Amgen’s price target?

The average price target for Amgen is 360.14. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $432.00 ,the lowest forecast is $185.00. The average price target represents -4.09% Decrease from the current price of $375.5.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Detailed List of Analyst Forecasts